Comparing schizophrenia and methamphetamine-related psychosis
Part of Mental health clinical trials.
This study compares people with schizophrenia to people whose psychosis was caused by methamphetamine use. Researchers will look at how these two groups differ, which may help improve diagnosis and treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old
- You are currently experiencing psychotic symptoms, such as hallucinations or delusions
- You either have a diagnosis of schizophrenia or have used methamphetamine
- You do not have a major brain condition like epilepsy or dementia
- You are able to take part in interviews
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for patterns in psychiatric symptoms among people who have psychotic symptoms caused by methamphetamine use. You may qualify if you are 18-65, haven't taken psychiatric medication for at least a month, and do not have certain other health conditions.
This study compares people who have psychosis from methamphetamine and also use cannabis with those who only have methamphetamine-induced psychosis. It aims to understand how cannabis may affect their symptoms.
This study looks at the electrical activity of the heart (ECG) in people who use methamphetamine, including those who develop psychosis from it. It compares them to healthy volunteers to see if methamphetamine affects heart function.
This study looks at people who have had psychosis for less than 4 years to understand how their symptoms change over time and how they respond to treatment. By using brain scans and other tests, researchers hope to find better ways to personalize care for early psychosis.
This study looks at how the brain processes information in people with early psychosis compared to healthy controls. It may help improve understanding and treatment of psychosis.
This study looks at brain chemicals involved in “glutamate” and “GABA” signaling in people with schizophrenia (and separately in healthy volunteers). It may help researchers understand what’s going wrong in the brain and guide future treatments.
Hear when a new Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.